OncoMed Loses Another Asset – Rosmantuzumab – And CEO Paul Hastings
Loss of anti-RSPO-3 antibody rosmantuzumab, partnered with Celgene, means a rough start to the year, following disappointments in 2017.
You may also be interested in...
Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.
The UK company, which postponed plans for a US offering in April, has taken the M&A route to secure a Nasdaq listing by combining with OncoMed.
Takeda and Molecular Templates will work to develop targeted engineered toxin bodies for multiple myeloma. Celgene decides against optioning OncoMed’s navicixizumab for ovarian cancer, while CRISPR and ViaCyte team up on type 1 diabetes.